Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania

Journal of Infectious Diseases

Volumn 204, Issue 2, 2011, Pages 282-290

  Liu, Enju ^a   Spiegelman, Donna ^a   Semu, Helen ^d   Hawkins, Claudia ^b   Chalamilla, Guerino ^a,d   Aveika, Akum ^d   Nyamsangia, Stella ^d   Mehta, Saurabh ^c   Mtasiwa, Deo ^e   Fawzi, Wafaie ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d MANAGEMENT AND DEVELOPMENT FOR HEALTH   (Tanzania)

^e MINISTRY OF HEALTH AND SOCIAL WELFARE   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RIFAMPICIN; STAVUDINE;

ADULT; ARM CIRCUMFERENCE; ARTICLE; BODY MASS; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL STATUS; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; TANZANIA; TREATMENT DURATION; WEIGHT REDUCTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BODY MASS INDEX; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NUTRITIONAL STATUS; TANZANIA;

EID: 79958745850     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir246     Document Type: Article

References (38)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2008. Available at: http://www.who.int/hiv/pub/2008progressreport/en/index.html. Accessed 03 May 2011.
2. Joint United Nations Programmes on HIV/AIDS and World Health Organization. AIDS epidemic update. Geneva, Switzerland, 2009. Available at: http://data.unaids.org/pub/Report/2009/jc1700-epi-update-2009-en.pdf. Accessed 03 May 2011.
3. Wanke CA, Silva M, Knox TA, Forrester J, Spiegelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 31:803-5. (Pubitemid 32295505)
4. Jerene D, Endale A, Hailu Y, Lindtjorn B. Predictors of early death in a cohort of Ethiopian patients treated with HAART. BMC Infect Dis 2006; 6:136-43.
5. Koethe JR, Heimburger DC. Nutritional aspects of HIV-associated wasting in sub-Saharan Africa. Am J Clin Nutr 2010; 91:1138S-1142S.
6. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21:2483-91. (Pubitemid 350145180)
7. Paton NI, Sangeetha S, Earnest A, Bellamy R. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy. HIV Med 2006; 7:323-30. (Pubitemid 43805693)
8. Sieleunou I, Souleymanou M, Schonenberger AM, Menten J, Boelaert M. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. Trop Med Int Health 2009; 14:36-43.
9. van der Sande MA, Schim van der Loeff MF, Aveika AA, et al. Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr 2004; 37:1288-94.
10. Hanrahan CF, Golub JE, Mohapi L, et al. Body mass index and risk of tuberculosis and death. AIDS 2010; 24:1501-8.
11. Marazzi MC, Liotta G, Germano P, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 2008; 24:555-60. (Pubitemid 351571039)
12. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20:2355-60. (Pubitemid 44789538)
13. Koethe JR, Lukusa A, Giganti MJ, et al. Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010; 53:507-13.
14. Madec Y, Szumilin E, Genevier C, et al. Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries. AIDS 2009; 27:853-61.
15. National Guidelines for the Management of HIV and AIDS, National AIDS Control Programme (NACP), 3rd ed., 2008.
16. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2006 revision. Available at: http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf. Accessed 03 May 2011.
17. Lohman TG, Roche AF,Martorell R eds: Anthropometric standardization reference manual. Champaign, IL: Human Kinetics Publishing, 1988.
18. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8:551-61. (Pubitemid 19116001)
19. Govindarajulu US, Spiegelman D, Thurston SW, Ganguli B, Eisen EA. Comparing smoothing techniques in Cox models for exposure-response relationships. Stat Med 2007; 26:3735-52. (Pubitemid 47307746)
20. World Health Organization. BMI classification. Global database on body mass index. Available at: http://apps.who.int/bmi/index.jsp?introPage5intro-3. html. Accessed 6 August 2010.
21. Shikuma CM, Zackin R, Sattler F, et al. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis 2004; 39:1223-30. (Pubitemid 40169323)
22. Hickey MS. Nutritional support of patients with AIDS. Surg Clin North Am 1991; 71:645-64.
23. Brown TT, Xu X, John M, et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther 2009; 6:8.
24. van Vonderen MG, van Agtmael MA, Hassink EA, et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One 2009; 4:e5647.
25. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62. (Pubitemid 40075680)
26. Tang AM. Weight loss, wasting, and survival in HIV-positive patients: current strategies. AIDS Read 2003; 13:S23-7.
27. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31:230-6. (Pubitemid 35190578)
28. Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS One 2010; 5:e10340.
29. Cantrell RA, Sinkala M, Megazinni K, et al. A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia J Acquir Immune Defic Syndr 2008; 49:190-5.
30. Swaminathan S, Padmapriyadarsini C, Yoojin L, et al. Nutritional supplementation in HIV-infected individuals in South India: a prospective interventional study. Clin Infect Dis 2010; 51:51-7.
31. Ndekha MJ, van Oosterhout JJ, Zijlstra EE, Manary M, Saloojee H, Manary MJ. Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial. BMJ 2009; 338:b1867.
32. Fawzi WW, Msamanga GI, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351:23-32. (Pubitemid 38857244)
33. Baum MK, Lai S, Sales S, Page JB, Campa A. Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults. Clin Infect Dis 2010; 50:1653-60.
34. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-10. (Pubitemid 44142772)
35. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2):15-23. (Pubitemid 352019086)
36. Sawe FK, McIntyre JA. Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes. Clin Infect Dis 2009; 49:463-5.
37. Moore DM, Awor A, Downing R, et al. CD41 T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477-84.
38. Steegen K, Luchters S, De Cabooter N, et al. Evaluation of 2 commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J Virol Methods 2007; 146:178-87. (Pubitemid 350026632)